Is NMN Legal? The FDA Ban and 2025 Reversal

The short answer, as of late 2025: yes, NMN is legal to buy and sell as a dietary supplement in the United States again. But that simple answer hides one of the strangest regulatory episodes in the supplement world — a three-year stretch in which the FDA declared NMN not a lawful supplement, Amazon pulled it from its shelves, and then the agency reversed itself. None of that back-and-forth was ever about whether NMN is safe or whether it works. It was a fight over which legal category NMN belongs in. Here's the precise timeline, what each step actually meant, and why "legal" doesn't mean "proven."

This is a regulatory explainer, not legal or medical advice. NMN is a supplement, not an FDA-approved drug, and nothing about its legal status implies it treats, prevents, or cures any condition.

The timeline at a glance

Step 1 — NMN was an openly sold supplement

For years, nicotinamide mononucleotide (NMN) — a precursor your cells convert into NAD+ — was sold across the US as a dietary supplement, and the FDA had even acknowledged new-dietary-ingredient (NDI) notifications for NMN ingredients. It sat on shelves and on Amazon like any other supplement. That history matters, because it becomes the legal hinge of the whole saga.

Step 2 — The November 2022 exclusion

On November 4, 2022, the FDA changed course and stated that NMN is excluded from the statutory definition of a dietary supplement. The basis was the "drug-preclusion" clause of the Federal Food, Drug, and Cosmetic Act (section 201(ff)(3)(B)). In plain terms, that clause says an ingredient can be barred from the supplement category if it was first authorized for investigation as a new drug — and substantial clinical investigations were instituted and made public — before it was marketed as a supplement. NMN had become the subject of a pharmaceutical investigational-new-drug (IND) program (a company was developing an NMN-based drug candidate), and the FDA invoked that to push NMN out of the supplement lane.

Critically, this was a category determination, not a safety action. The FDA did not cite any new evidence of harm, and the human safety data on oral NMN at studied doses has been reassuring across trials¹². Industry groups — led by the Natural Products Association (NPA) — argued this was the first time the agency had reversed a dietary-ingredient acknowledgment on drug-preclusion grounds without any safety concern.

Step 3 — Amazon delists NMN (March 2023)

Citing the FDA's position, Amazon told sellers they could list NMN products only until March 13, 2023, after which NMN supplements were removed from the platform. For most consumers, this is the moment NMN seemed to "disappear" — even though it was never illegal to possess or to use, and many other retailers kept selling it. The delisting was a marketplace policy decision driven by the FDA's category call, not a law banning the molecule.

Step 4 — The industry pushes back

The exclusion didn't go unchallenged. The NPA filed a citizen petition with the FDA, then escalated to a federal lawsuit in Washington, DC, arguing the agency had misapplied the drug-preclusion clause. The core counterargument rested on the so-called "race-to-market" provision: the drug-preclusion bar only applies if the drug investigation came first. If NMN had been marketed as a supplement before the drug investigation was authorized, it keeps its eligibility as a dietary ingredient.

Step 5 — The September 2025 reversal

In letters dated September 29, 2025, the FDA reconsidered and concluded that NMN is not excluded from the dietary-supplement definition after all. The agency determined there was sufficient evidence that NMN had been marketed as a supplement in the US before it was authorized for drug investigation — satisfying the race-to-market provision and preserving its status as a lawful dietary ingredient. NMN products began returning to major retailers.

Two nuances worth keeping straight, because the celebratory headlines blurred them:

• •NMN is still a New Dietary Ingredient (NDI). "Lawful to sell" doesn't mean "unregulated." NMN still requires an NDI notification pathway; a brand can generally rely on a prior notification only if it sources from the same supplier that filed it. The reversal restored eligibility — it didn't remove the NDI framework.
• •It was never a verdict on efficacy or safety. The entire 2022–2025 fight was about statutory category and the timing of a drug program, not about trial data. If you avoided NMN because you thought the FDA found it dangerous, that was a misreading.

What about outside the US? EU and Australia are different stories

"Legal in the US" does not generalize. NMN's status varies sharply by jurisdiction, and the picture as of late 2025 is genuinely mixed:

• •European Union — not freely sold. In the EU, NMN is treated as a novel food, which means it requires pre-market authorization before it can be sold as a food or supplement. As of late 2025, multiple NMN novel-food applications were working through the European Food Safety Authority (EFSA) review process, but no NMN product had yet received full EU authorization. So in practice, NMN is not a freely lawful supplement across the EU — it's pending, not approved. (This is a regulatory gate, not a safety ban.)
• •Australia — newly permitted, with conditions. Australia's Therapeutic Goods Administration (TGA) added NMN to its permitted-ingredients determination in December 2025, allowing it as an oral active ingredient in listed medicines, capped at 500 mg/day, initially tied to a specific sponsor. Before that, NMN supplements could be made in Australia only for export. This made Australia one of the first countries to formally permit NMN as a supplement ingredient.

The takeaway: NMN's legality is a moving, country-by-country target. US-lawful-again is the headline, but an EU buyer and a US buyer are in very different regulatory positions.

"Legal" is not "proven" — the part the headlines skip

It's worth being blunt about what legality does and doesn't tell you. A supplement being lawful to sell says nothing about whether it delivers the benefits on the label. The honest evidence picture for NMN is unchanged by any of this regulatory drama: oral NMN reliably raises the NAD+ biomarker in human blood and is well tolerated at studied doses²³, but its most-cited downstream human result — improved muscle insulin sensitivity in prediabetic women — was narrow and publicly contested⁴, and there's no robust human evidence that NMN extends lifespan or reverses aging. "You can legally buy it" and "it does what the ad says" are entirely separate claims. We rate the products by evidence and third-party purity in our best NMN supplements guide, and unpack the felt-benefit gap (a big reason people stop taking NMN) separately.

One more clarification that trips people up: NMN is a precursor, not NAD+ itself — buying "NMN" is not the same as supplementing NAD+ directly, a distinction we cover in NMN vs NAD+: what's the difference. And because the category's purity oversight stayed thin throughout the regulatory chaos, a batch-specific Certificate of Analysis matters more for NMN than for many supplements.

Bottom line

Is NMN legal? In the US, yes — it's a lawful dietary supplement again after the FDA's September 29, 2025 reversal, which restored its eligibility on race-to-market grounds (it's still an NDI, just not an excluded one). The 2022 exclusion and the March 2023 Amazon delisting were a statutory-category dispute driven by the timing of a drug program, never a safety or efficacy finding. Outside the US it's murkier: NMN is a pending novel food in the EU (not yet freely sold) and newly permitted with conditions in Australia. And through all of it, the science didn't change — NMN raises NAD+ reliably and proves its felt benefits poorly, regardless of what shelf it's allowed on. For the underlying evidence, start with our NAD+ therapy pillar and compare vetted options in our best NAD+ hub.